Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib combinations in advanced cervical cancer
NCT04395612Phase 2Unknown
- Sponsor
- Chongqing University Cancer Hospital
- Start
- May 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of niraparib in Cervical Cancer (CC) (2 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Drugs
niraparib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04395612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04395612.